Startups
IDRx aims to create highly selective and aligned drug combinations to stop key tumor escape mechanisms that will support prolonged and durable responses to therapy.
Vicinitas launched with a Series A round worth $65 million and was co-led by a16z and Deerfield Management, with participants including Droia Ventures, GV, and the Berkeley Catalyst Fund.
The result will be two independent, publicly traded companies: Labcorp and The Clinical Development Business offering Phase I-IV clinical trial management and technology to the biopharma industry.
Martin Shkreli, commonly known as the “Pharma Bro,” announced Monday he has cofounded Druglike, a Web3 drug discovery software platform, despite a lifetime ban from the pharma industry.
Auron Therapeutics reels in $48 million to identify novel AI-based cancer targets, Frontera scoops up $160 million for AAV gene therapy and tech manufacturing and MMI scores $75 million for robotic microsurgery.
GSK, whose shares were up about 3.3% Monday, will likely use part of the 7 billion pounds it will generate via the Haleon spinoff to make acquisitions.
Founded by George Church, known by many as the Father of Genomics, Manifold Bio launched with a $40 million Series A financing round to advance its “protein barcoding” platform.
Backed by biopharma royalty, Areteia Therapeutics will focus on developing an old molecule for a very prevalent disease - asthma.
Flagship Pioneering has launched Apriori Bio, which utilizes artificial intelligence to predict virus activity and variant formation, including COVID-19.
When GSK’s consumer health spinoff Haleon launches later this month, the new business will carry more than $12 billion in debt when it lists on the London Stock Exchange.
PRESS RELEASES